Plant Name: Terminalia chebula
Taxonomic Information:
Plant ID: NPO26650
Plant Latin Name: Terminalia chebula
Taxonomy Genus: Terminalia
Taxonomy Family: Combretaceae
Plant External Links:
NCBI TaxonomyDB:
155022
Plant-of-the-World-Online:
171037-1
Used in Medicines:
Country/Region:
Thailand; China; India; PakistanTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyGeographical Distribution:
Pakistan; Bangladesh; Myanmar; Nepal; India; Cambodia; Vietnam; China; Laos; Sri Lanka; Thailand; Taiwan
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; ADRA2B; GPR35; | |
| RECQL; TDP1; BLM; PKM; HPGD; AKR1B1; HSD17B10; ALOX15; NOX4; USP2; POLB; APEX1; | |
| TOP1; | |
| TEK; INSR; FLT3; MAPK1; MAPK14; EGFR; MET; SRC; KDR; IGF1R; LCK; FYN; NUAK1; CSNK2A1; | |
| CA2; CA12; CA7; CA4; CA6; | |
| PPARA; | |
| KDM4E; | |
| BACE1; | |
| MMP12; | |
| HIF1A; | |
| FUT7; | |
| SLC22A6; | |
| SMAD3; LMNA; FABP3; FABP5; FABP4; HSPA1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Isomerase | TOP1 | DNA topoisomerase I | P11387 | CHEMBL1781 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.143E-11 | 4.148E-08 | EGFR, FYN, IGF1R, INSR, KDR, LCK, SRC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.152E-10 | 2.205E-07 | CA12, CA2, CA4, CA6, CA7 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 7.485E-09 | 2.469E-06 | BLM, CSNK2A1, EGFR, FLT3, FYN, HSPA1A, IGF1R, INSR, KDR, LCK, MAPK1, MAPK14, MET, NUAK1, PKM, RECQL, SRC, TEK, TOP1 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 9.357E-09 | 2.911E-06 | EGFR, FYN, INSR, LCK, MET, NOX4, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.985E-08 | 1.234E-05 | CA12, CA2, CA4, CA6, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.412E-07 | 2.795E-05 | CA12, CA2, CA4, CA6, CA7 |
| MF | Unclassified; | GO:0032403; protein complex binding | 2.046E-07 | 3.908E-05 | APEX1, EGFR, FLT3, FYN, IGF1R, INSR, KDR, LCK, MMP12, PKM, PPARA, SMAD3, SRC |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 5.726E-07 | 9.305E-05 | HIF1A, LMNA, NOX4, PKM, PPARA, SMAD3, SRC, TEK |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 9.126E-07 | 1.370E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.218E-06 | 1.733E-04 | ALOX15, EGFR, FFAR4, KDR, NOX4, SRC, TEK |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.230E-06 | 1.735E-04 | FYN, IGF1R, INSR, LCK |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.498E-06 | 2.078E-04 | CYP1A2, CYP1B1, CYP2C9, NOX4, SRC, TBXAS1 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.714E-06 | 2.262E-04 | EGFR, INSR, KDR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.444E-06 | 3.041E-04 | CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.883E-06 | 6.437E-04 | BLM, CSNK2A1, EGFR, FLT3, FYN, HPGD, IGF1R, KDR, L3MBTL1, LCK, MAPK1, MET, PKM, SLC22A6, SMAD3, USP2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.464E-06 | 7.929E-04 | CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.671E-06 | 8.069E-04 | APEX1, POLB |
| MF | GO:0005488; binding | GO:0042610; CD8 receptor binding | 7.671E-06 | 8.069E-04 | FYN, LCK |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.294E-05 | 1.269E-03 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.384E-05 | 1.352E-03 | ADRA2B, FYN, LCK, MAPK1, SRC |
| BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 1.692E-05 | 1.616E-03 | ALOX15, HSPA1A, MET, NOX4, SMAD3, TEK |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.297E-05 | 2.084E-03 | CA2, CA7 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.436E-05 | 2.191E-03 | CA2, CA7, FYN, KDR, LCK, SRC |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.651E-05 | 2.366E-03 | CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 2.698E-05 | 2.398E-03 | CA2, CSNK2A1, CYP1A2, EGFR, FABP3, FFAR1, FLT3, HPGD, MAPK14, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 3.103E-05 | 2.692E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 3.457E-05 | 2.964E-03 | FLT3, FYN, KDR, TEK |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 3.457E-05 | 2.964E-03 | EGFR, FYN, LCK, MET |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 4.277E-05 | 3.528E-03 | FABP3, INSR, PKM, PPARA, SRC |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.548E-05 | 3.712E-03 | FABP3, FABP4, FABP5 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.586E-05 | 3.712E-03 | CYP1A2, CYP2C9 |
| CC | GO:0016020; membrane | GO:0005901; caveola | 4.613E-05 | 3.720E-03 | INSR, MAPK1, SLC22A6, SRC |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 4.823E-05 | 3.845E-03 | EGFR, FFAR1, HIF1A, MAPK14, MMP12, SRC |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.874E-05 | 3.845E-03 | FYN, KDR, MAPK14, SRC |
| CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 4.874E-05 | 3.845E-03 | ALOX15, FYN, LCK, SRC |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 6.028E-05 | 4.574E-03 | CSNK2A1, EGFR, FLT3, PKM |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 6.346E-05 | 4.748E-03 | ALOX15, EGFR, PPARA, SMAD3 |
| BP | GO:0009987; cellular process | GO:0046427; positive regulation of JAK-STAT cascade | 6.346E-05 | 4.748E-03 | AKR1B1, CYP1B1, FLT3, FYN |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.345E-05 | 5.385E-03 | BLM, CA12, CA2, CA4, CA6, CA7, L3MBTL1, MMP12, PPARA, SMAD3 |
| MF | GO:0005488; binding | GO:0051525; NFAT protein binding | 7.630E-05 | 5.465E-03 | MAPK14, PPARA |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 7.630E-05 | 5.465E-03 | BLM, RECQL |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 7.949E-05 | 5.656E-03 | FLT3, SRC, TEK |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.348E-05 | 5.883E-03 | ALOX15, CYP1A2, CYP1B1, CYP2C9, TBXAS1 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 8.783E-05 | 6.033E-03 | CYP1A2, EGFR, MAPK1 |
| BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 8.852E-05 | 6.062E-03 | APEX1, FYN, INSR, PKM, SRC |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 9.339E-05 | 6.285E-03 | EGFR, IGF1R, INSR, PKM |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 9.672E-05 | 6.402E-03 | CSNK2A1, HIF1A, KDR |
| BP | GO:0002376; immune system process | GO:0045321; leukocyte activation | 9.922E-05 | 6.488E-03 | FABP5, FLT3, FUT7, FYN, HSPA1A, LCK, MAPK1, MAPK14, PKM, SMAD3 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.035E-04 | 6.750E-03 | AKR1B1, APEX1, BLM, CSNK2A1, FABP5, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, MAPK1, MAPK14, NUAK1, POLB, PPARA, RECQL, SMAD3, SRC, TOP1, USP2 |
| BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.062E-04 | 6.841E-03 | HIF1A, PPARA, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.062E-04 | 6.841E-03 | INSR, PPARA, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0001819; positive regulation of cytokine production | 1.097E-04 | 7.006E-03 | CYP1B1, HIF1A, HSPA1A, MAPK14, MMP12, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.142E-04 | 7.232E-03 | ALOX15, HPGD |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.142E-04 | 7.232E-03 | CYP1A2, CYP2C9 |
| BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.162E-04 | 7.315E-03 | ADRA2B, INSR, SRC |
| MF | GO:0005488; binding | GO:0019904; protein domain specific binding | 1.196E-04 | 7.486E-03 | FYN, HIF1A, HSPA1A, INSR, L3MBTL1, LCK, PPARA, SRC, TOP1 |
| BP | GO:0009987; cellular process | GO:1902905; positive regulation of supramolecular fiber organization | 1.206E-04 | 7.503E-03 | ALOX15, HSPA1A, MET, NOX4, SMAD3 |
| BP | GO:0008283; cell proliferation | GO:0050679; positive regulation of epithelial cell proliferation | 1.273E-04 | 7.830E-03 | EGFR, HIF1A, KDR, MMP12, TEK |
| BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.307E-04 | 8.019E-03 | BLM, CSNK2A1, L3MBTL1, MAPK14, NUAK1 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.317E-04 | 8.055E-03 | CA2, EGFR, HIF1A, MET, SMAD3, SRC |
| MF | GO:0003824; catalytic activity | GO:0004497; monooxygenase activity | 1.438E-04 | 8.628E-03 | CYP1A2, CYP1B1, CYP2C9, TBXAS1 |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.597E-04 | 9.345E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.597E-04 | 9.345E-03 | FLT3, KDR |
| MF | GO:0005488; binding | GO:0042608; T cell receptor binding | 1.597E-04 | 9.345E-03 | FYN, LCK |
| MF | GO:0005488; binding | GO:0042609; CD4 receptor binding | 1.597E-04 | 9.345E-03 | FYN, LCK |
| MF | GO:0003824; catalytic activity | GO:0043140; ATP-dependent 3'-5' DNA helicase activity | 1.597E-04 | 9.345E-03 | BLM, RECQL |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.622E-04 | 9.468E-03 | EGFR, MAPK1, MAPK14, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 1.687E-04 | 9.794E-03 | EGFR, FYN, LCK, MET |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.657E-13 | 6.035E-11 | SMAD3, CSNK2A1, SRC, INSR, MAPK1, FYN, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 4.812E-09 | 2.647E-07 | SRC, INSR, KDR, MAPK1, TEK, MAPK14, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.842E-08 | 2.258E-06 | SRC, KDR, MAPK1, MAPK14, HIF1A, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.559E-08 | 1.056E-06 | PKM, FLT3, MAPK1, MET, HIF1A, EGFR |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.164E-10 | 5.911E-08 | CA12, CA2, CA4, CA7, CA6 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.405E-07 | 9.363E-06 | INSR, MAPK1, TEK, HIF1A, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.145E-06 | 2.698E-05 | SRC, KDR, MAPK1, FYN, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.490E-06 | 4.564E-05 | INSR, KDR, MAPK1, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.535E-06 | 3.166E-05 | SMAD3, INSR, MAPK1, MAPK14, EGFR, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 5.935E-06 | 9.792E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 1.937E-05 | 2.905E-04 | SRC, TBXAS1, MAPK1, FYN, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.505E-05 | 3.962E-04 | INSR, KDR, MAPK1, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.209E-05 | 3.038E-04 | SRC, KDR, MAPK1, MAPK14 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.400E-05 | 3.962E-04 | SRC, MAPK14, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 9.130E-05 | 8.370E-04 | SMAD3, FLT3, MAPK1, HIF1A, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 4.032E-05 | 4.159E-04 | MAPK1, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.066E-04 | 9.256E-04 | SRC, MAPK1, MAPK14, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.602E-05 | 3.962E-04 | FABP3, FABP4, FABP5, PPARA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.477E-04 | 1.161E-03 | SRC, MAPK1, EGFR, HSPA1A |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.787E-04 | 1.323E-03 | LCK, MAPK1, FYN, MAPK14 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 4.440E-04 | 2.792E-03 | LCK, MAPK1, FYN, MAPK14 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 4.569E-04 | 2.792E-03 | MAPK1, MAPK14, PPARA, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 6.164E-04 | 3.458E-03 | INSR, MAPK1, FYN, EGFR |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 5.849E-04 | 3.446E-03 | SMAD3, MAPK1, MAPK14, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.334E-04 | 2.200E-03 | INSR, CYP1B1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 2.953E-04 | 2.030E-03 | PKM, INSR, MAPK1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05020 | Prion diseases | 1.145E-04 | 9.450E-04 | MAPK1, FYN, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.844E-04 | 1.323E-03 | SRC, MAPK1, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 6.469E-05 | 6.279E-04 | CYP2C9, CYP1A2, ALOX15 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 7.220E-04 | 3.559E-03 | MAPK1, EGFR, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 6.900E-04 | 3.559E-03 | INSR, HSPA1A, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 6.287E-04 | 3.458E-03 | CYP2C9, ALOX15, TBXAS1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 8.236E-04 | 3.775E-03 | MAPK1, FYN, MAPK14 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.413E-03 | 5.846E-03 | HPGD, FLT3, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 7.549E-04 | 3.559E-03 | SMAD3, MAPK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 7.549E-04 | 3.559E-03 | MAPK1, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.271E-03 | 8.328E-03 | POLB, PKM, SRC, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 9.727E-04 | 4.338E-03 | SRC, MAPK1, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.680E-03 | 6.698E-03 | SRC, MAPK1, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 7.220E-04 | 3.559E-03 | SRC, MAPK1, MAPK14 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.572E-03 | 8.662E-03 | SMAD3, MAPK1, MAPK14 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.793E-03 | 6.725E-03 | MAPK1, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.361E-03 | 8.444E-03 | MAPK1, MAPK14, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.012E-03 | 4.396E-03 | CYP2C9, CYP1A2, CYP1B1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.736E-03 | 6.698E-03 | SRC, MAPK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.572E-03 | 8.662E-03 | MAPK1, HIF1A, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.417E-03 | 5.846E-03 | CYP2C9, CYP1A2, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 2.795E-03 | 9.223E-03 | SMAD3, MAPK1, MAPK14 |
| Unclassified | Unclassified | hsa04320 | Dorso-ventral axis formation | 2.405E-03 | 8.444E-03 | MAPK1, EGFR |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.746E-03 | 6.698E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; FFAR1; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | TOP1; EGFR; SRC; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; TOP1; IGF1R; KDR; CSNK2A1; FLT3; HIF1A; TEK; MAPK1; MAPK14; EGFR; SRC; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
| C00-D49: Neoplasms | Advanced ovarian cancer | NA | TOP1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; PKM; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | TOP1; IGF1R; KDR; FLT3; INSR; EGFR; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | TOP1; KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | TOP1; KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TOP1; KDR; EGFR; |
| NA: NA | Inflammatory diseases | NA | MAPK14; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | TOP1; KDR; EGFR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; TBXAS1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; MAPK14; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | LCK; INSR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TOP1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; INSR; EGFR; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14; TBXAS1; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; MAPK14; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; MAPK14; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | TOP1; EGFR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | TOP1; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | TOP1; FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1; |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| NA: NA | Edema | NA | CA2; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TOP1; KDR; TEK; |
| NA: NA | Rheumatold arthritis | NA | MAPK14; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MAPK14; AKR1B1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | TOP1; EGFR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; TOP1; IGF1R; KDR; FLT3; HIF1A; TEK; MAPK1; EGFR; SRC; PKM; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; TBXAS1; FFAR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; MAPK14; EGFR; |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TOP1; IGF1R; KDR; FLT3; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14; |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | TOP1; |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
